8-K: Lineage Cell Therapeutics Reports Positive Data and Financial Results for 2024

Lineage Cell Therapeutics announces positive clinical data for OpRegen, a services agreement with Genentech, and financial results for 2024, with cash runway extended into Q1 2027.

Summary

• Lineage Cell Therapeutics reported its fourth quarter and full year 2024 financial and operating results.
• The company highlighted positive 24-month visual acuity data with OpRegen in geographic atrophy patients.
• Lineage signed a services agreement with Genentech to support OpRegen development.
• OpRegen received RMAT designation from the FDA.
• The company completed two financings totaling $44 million in gross proceeds, with a potential additional $36 million upon full cash exercise of clinical milestone-linked warrants.
• Lineage initiated a device delivery study for OPC1 in patients with subacute and chronic spinal cord injury.
• The company hosted its annual Spinal Cord Injury Symposium with the Christopher & Dana Reeve Foundation.
• Preclinical results for ReSonance (ANP1) were presented at the 59th Annual Inner Ear Biology Workshop.
• Cash, cash equivalents, and marketable securities totaled $47.8 million as of December 31, 2024.
• Revenues for the year ended December 31, 2024, were $9.5 million, an increase of $0.6 million compared to 2023.
• The net loss attributable to Lineage for the year ended December 31, 2024, was $18.6 million, or $0.09 per share.
• Lineage expects its cash to support planned operations into Q1 2027.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data, strategic partnerships, and a strengthened financial position. However, ongoing losses and inherent risks in drug development temper the overall sentiment.

Positives

• Positive clinical data for OpRegen suggests potential for treating geographic atrophy.
• The services agreement with Genentech validates the OpRegen program and provides additional support.
• RMAT designation for OpRegen could expedite its development and review process.
• Successful financings have strengthened the company's balance sheet.
• Initiation of the DOSED study represents progress in the OPC1 program for spinal cord injuries.
• Increased revenues indicate growing collaboration and licensing success.
• Reduced net loss reflects improved financial performance.
• Strong cash position provides runway into Q1 2027.

Negatives

• The company continues to operate at a loss, with a net loss of $18.6 million for 2024.
• General and administrative expenses increased by $0.9 million compared to the same period in 2023.

Risks

• Development activities and clinical trials may not progress as expected.
• Positive early clinical results may not be predictive of success in later trials.
• Roche and Genentech may not successfully advance OpRegen.
• Competing therapies could impact the commercial potential of OpRegen.
• The ongoing Israeli regional conflict may materially and adversely impact manufacturing processes.
• Lineage may not be able to manufacture sufficient clinical quantities of its product candidates.

Future Outlook

Lineage anticipates advancing its programs through important milestones during 2025, focusing on the DOSED clinical study, advancing ReSonance, and demonstrating in-house manufacturing capabilities.

Management Comments

• Throughout 2024, we made substantial progress across multiple fronts, advancing our programs, expanding collaborations, and strengthening our balance sheet to support significant anticipated milestones, stated Brian M. Culley, Lineages CEO.
• We anticipate our internal programs will similarly advance through important milestones during 2025, added Mr. Culley.
• As the power of our cell differentiation and manufacturing platforms are further demonstrated and validated, we believe that our pipeline of internally-owned assets and cell-based know-how will make us a desirable development partner and an attractive opportunity for investors.

Industry Context

Lineage's focus on allogeneic cell therapies for neurological conditions aligns with the growing interest in regenerative medicine and cell-based therapies. The collaboration with Roche and Genentech highlights the potential of OpRegen in the competitive AMD market.

Comparison to Industry Standards

• Lineage's collaboration with Roche and Genentech for OpRegen is similar to other partnerships in the cell therapy space, such as Novartis' collaboration with Cellularity for allogeneic CAR-T cell therapies.
• The RMAT designation for OpRegen is comparable to similar designations received by companies like CRISPR Therapeutics for their gene-edited cell therapies.
• Lineage's cash runway into Q1 2027 is relatively strong compared to other clinical-stage biotech companies, providing financial stability for ongoing development programs.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical data and strengthened financial position.
• Employees may benefit from the company's progress and potential for future growth.
• Patients with geographic atrophy and spinal cord injuries may have access to new treatment options.
• The collaboration with Roche and Genentech could lead to increased opportunities for suppliers and partners.

Next Steps

• Continue execution of Lineage's contributions to the collaboration with Roche and Genentech.
• Advance the DOSED clinical study for OPC1.
• Further develop ReSonance for the treatment of sensorineural hearing loss.
• Demonstrate an in-house manufacturing capability for allogeneic cell banking and production.

Key Dates